Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients

NCT05202340 | Completed

• 1 other identifier: CRE-2021.492
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients. This is a cross-sectional study performed in Prince of Wales Hospital in Hong Kong. One hundred patients will be recruited for this study.

Conditions

Prostate Cancer

Keywords

Prostate Cancer; Androgen Deprivation Therapy

Outcome Measures

Primary Outcomes (1)

• Possible factors that will affect patient's choice of ADT therapy

  Possible factors that will affect patient's choice of ADT therapy

  1 year

Study Arms (1)

Prostate Cancer

Patients diagnosed with prostate cancer

Other: No intervention

Interventions

No intervention OTHER

No intervention

Prostate Cancer

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Prostate cancer only happens in male patients
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with prostate cancer in Prince of Wales Hospital will be identified in specialist clinics and then enrolled to the study,

You may qualify if:

• Prostate cancer only happens in male patients
• Patients who are currently receiving at least one dose of LHRH agonist or antagonist, as androgen deprivation therapy
• Patients who are willing to consent and participate in this study

You may not qualify if:

• Patients who received bilateral orchidectomy as androgen deprivation therapy
• Patients who, in the opinion of investigators, are not able to comprehend about the study questions

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Prince of Wales Hospital

Shatin, Hong Kong

Location

Related Publications (3)

• Psarou A, Cooper H, Wilding JPH. Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. Diabetes Ther. 2018 Oct;9(5):1791-1810. doi: 10.1007/s13300-018-0490-5. Epub 2018 Aug 17.

  PMID: 30120753 BACKGROUND

• Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Patient Prefer Adherence. 2020 Jul 2;14:1093-1102. doi: 10.2147/PPA.S251812. eCollection 2020.

  PMID: 32753849 BACKGROUND

• Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19.

  PMID: 14640142 BACKGROUND

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Chi Fai NG, MD

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 9, 2022
• First Posted: January 21, 2022
• Study Start: January 7, 2022
• Primary Completion: December 31, 2022
• Study Completion: February 28, 2023
• Last Updated: June 1, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)